ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

CATX Perspective Therapeutics Inc

4.12
0.00 (0.00%)
Pre Market
Last Updated: 09:00:02
Delayed by 15 minutes
Share Name Share Symbol Market Type
Perspective Therapeutics Inc AMEX:CATX AMEX Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 4.12 10 09:00:02

Perspective Therapeutics to Participate in Upcoming Investor Conferences in December

27/11/2024 12:00pm

GlobeNewswire Inc.


Perspective Therapeutics (AMEX:CATX)
Intraday Stock Chart


Friday 29 November 2024

Click Here for more Perspective Therapeutics Charts.

Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences.

36th Annual Piper Healthcare ConferenceDate: December 3, 2024Location: New York, NYFormat: Fireside ChatTime: 10:00-10:25 AM ET

7th Annual Evercore HealthCONxDate: December 5, 2024Location: Coral Gables, FLFormat: Fireside ChatTime: 10:50-11:10 AM ET

Webcast events can be accessed live, and replays will be archived for 90 days and available through the Investors page on the Perspective website at https://perspectivetherapeutics.com/investor-center. 

About Perspective Therapeutics, Inc.Perspective Therapeutics, Inc., is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. The Company is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.

The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary 212Pb generator to secure key isotopes for clinical trial and commercial operations.

For more information, please visit the Company's website at www.perspectivetherapeutics.com.

Media and Investor Relations Contacts:

Perspective Therapeutics IR:
Annie J. Cheng, CFA
ir@perspectivetherapeutics.com

Russo Partners, LLC
Nic Johnson

PerspectiveIR@russopr.com

1 Year Perspective Therapeutics Chart

1 Year Perspective Therapeutics Chart

1 Month Perspective Therapeutics Chart

1 Month Perspective Therapeutics Chart

Your Recent History